Business Standard

Manufacturing segment will grow fast over the next decade: Syngene CEO

In a Q&A, Jonathan Hunt talks about his company's capex plans and strategic initiatives going forward

Syngene CEO and MD Jonathan Hunt
Premium

Syngene CEO and MD Jonathan Hunt

Sohini DasDeepsekhar Choudhury Mumbai/Bengaluru
Biotech contract research firm Syngene saw its revenue from operations grow 10 per cent to Rs 641 crore in Q3 on a year-on-year basis, while profit before tax also grew 10 per cent to Rs 128 crore. Syngene CEO and MD Jonathan Hunt spoke to Sohini Das and Deepsekhar Choudhury about the company’s capex plans and strategic initiatives going forward. Edited excerpts:

What kind of capex would you have to undertake for the Amgen project?

The Amgen capex is already covered in our multi-year capex plan. It is not a transformational amount or a trend break on the amount of

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 20 2022 | 6:14 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com